NBP — NovaBridge Biosciences Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for NovaBridge Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 673 | 500 | 312 | 173 | 211 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 59.3 | 1.19 | 1.79 | 1.04 | 1.67 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 753 | 526 | 330 | 177 | 218 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 25 | 18 | 5.55 | 3.8 | 2.95 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 882 | 591 | 369 | 213 | 261 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 98.2 | 110 | 58.1 | 8.45 | 26.9 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 164 | 169 | 126 | 11.5 | 29.6 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 718 | 422 | 243 | 201 | 231 |
| Total Liabilities & Shareholders' Equity | 882 | 591 | 369 | 213 | 261 |
| Total Common Shares Outstanding |